Andrew Kraft to Adult
This is a "connection" page, showing publications Andrew Kraft has written about Adult.
Connection Strength
0.098
-
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
Score: 0.052
-
Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec; 9(6):599-606.
Score: 0.012
-
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999 Jan 01; 85(1):178-87.
Score: 0.011
-
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
Score: 0.008
-
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40.
Score: 0.006
-
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8.
Score: 0.004
-
A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep; 5(9):2344-8.
Score: 0.003
-
[Neo-adjuvant chemotherapy of head and neck cancer]. Dtsch Med Wochenschr. 1986 Jul 11; 111(28-29):1097-100.
Score: 0.001